x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011763
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse |
| Applications | WB, IHC |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino-terminus of human APS. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SH2B2 |
| UniProt No. | O14492 |
| Gene ID | 10603 |
| Gene Description | APS is an SH2 and PH domain-containing adaptor protein closely related to Lnk and SH2-B. APS was identified as a substrate for many receptor tyrosine kinases including TrkA, insulin receptor, c-Kit and PDGF receptor. Tyrosine phosphorylation of APS provides docking sites for downstrean signaling components, mediating diverse signaling pathways. APS plays quite different roles in RTK signaling. Overexpression of APS has been shown to inhibit PDGF-induced mitogenicity, which may result from APS/c-Cbl-mediated PDGF receptor degradation. However, APS promotes enhanced mitogenicity in response to insulin stimulation. The striking difference in APS-mediated signaling between the different RTKs could lie in the mode of interaction with the respective receptor. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
